6:31 PM
 | 
Sep 21, 2007
 |  BC Extra  |  Clinical News

Maxygen off on Maxy-alpha hold

MAXY fell $0.77 to $7.47 on 2.2 million shares on Friday after partner Roche (SWX:ROG) voluntarily placed the Maxy-alpha HBV and HCV program on hold. The move came after "an...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >